☆ 4.6 Letter

Letter by Brutsaert and De Keulenaer Regarding Article, Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction

CIRCULATION-HEART FAILURE (2015)

Journal

CIRCULATION-HEART FAILURE

Volume 8, Issue 4, Pages 839-839

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/CIRCHEARTFAILURE.115.002236

Keywords

-

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction

Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz

Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.

CIRCULATION (2022)

Add to Collection

Letter Medicine, General & Internal

Dapagliflozin in Heart Failure with Preserved Ejection Fraction

Elric Zweck, Ralf Westenfeld, Bjorn Redfors, Elmir Omerovic, Robin A. P. Weir, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala, Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray

Summary: Solomon et al. report on the DELIVER trial, which showed that dapagliflozin reduced risks of heart failure-related outcomes in patients with a mildly reduced or preserved left ventricular ejection fraction. These findings are expected to influence guidelines and clinical practice. The trial also confirmed dapagliflozin's efficacy in patients with a left ventricular ejection fraction of 60% or above.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling

Jason Stencel, Hamid R. Alai, Aneesh Dhore-patil, Daniela Urina-Jassir, Thierry H. Le Jemtel

Summary: Preserved ejection fraction heart failure in obese individuals has become common in clinical practice due to the obesity epidemic. It is challenging to determine if obesity enables the development of preserved ejection fraction heart failure or if it is a convergence of two prevalent conditions. However, the obese phenotype of preserved ejection fraction heart failure provides an opportunity to study the effects of bariatric surgery on reversing left ventricular remodeling.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Critical Care Medicine

Sex-Related Differences in Dynamic Right Ventricular-Pulmonary Vascular Coupling in Heart Failure With Preserved Ejection Fraction

Inderjit Singh, Rudolf K. F. Oliveira, Paul M. Heerdt, Rosa Pari, David M. Systrom, Aaron B. Waxman

Summary: Male patients with HFpEF showed more compromised dynamic RV-PA uncoupling and reduced peak VO2 compared to female patients. This was due to impaired RV contractility and afterload mismatch, while female patients with HFpEF maintained RV-PA coupling during exercise and had better peak exercise VO2 compared to male patients.

CHEST (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Failure With Preserved Ejection Fraction

Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, Jennifer E. Ho

Summary: The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing due to aging, obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in understanding its pathophysiological effects and introduction of new diagnosis approaches, HFpEF remains under-recognized. This is concerning as effective treatments have been identified. This article provides an in-depth examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. (J Am Coll Cardiol 2023;81:1810-1834) (c) 2023 by the American College of Cardiology Foundation.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, Faiez Zannad, Anne Pernille Ofstad, Joao Pedro Ferreira, Jennifer B. Green, Julio Rosenstock, Sven Schnaidt, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker

Summary: In patients with heart failure and preserved ejection fraction, empagliflozin significantly reduces the risk of heart failure outcomes, regardless of diabetes status at baseline.

CIRCULATION (2022)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao P. Ferreira, Edimar Bocchi, Michael Boehm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L. Januzzi, Jose R. Gonzalez-Juanatey, Bela Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Pina, Piotr Ponikowski, Michele Senni, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Peter Carson, Carolyn Su Ping Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet M. Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, Milton Packer

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Debdatta Bhattacharyya, Ayan Kar, Saurabh Dhumale, Filippos K. Triposkiadis, Andrew Xanthopoulos, Efstathios K. Iliodromitis, James Amato, Hiddo J. L. Heerspink, Lesley Inker, Tom Greene, Stefan D. Anker, Javed Butler, Milton Packer

Summary: In patients with heart failure and preserved ejection fraction, Empagliflozin reduced the incidence of primary outcome events compared to other drugs, but had higher rates of cardiovascular death, death from any cause, and hospitalization for heart failure compared to spironolactone.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Heart Failure With Preserved Ejection Fraction: A Review

Margaret M. Redfield, Barry A. Borlaug

Summary: HFpEF affects approximately 3 million people in the US and up to 32 million people worldwide, and risk factors include older age, hypertension, diabetes, dyslipidemia, and obesity. First-line therapy for HFpEF includes sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed, and weight loss for patients with obesity and HFpEF.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction

Riccardo M. Inciardi, Martin Abanda, Amil M. Shah, Maja Cikes, Brian Claggett, Hicham Skali, Muthiah Vaduganathan, Narayana Prasad, Sheldon Litwin, Bela Merkely, Annamaria Kosztin, Klaudia Vivien Nagy, Sanjiv J. Shah, Wilfred Mullens, Michael R. Zile, Carolyn S. P. Lam, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon, PARAGON HF Investigators

Summary: This study aimed to evaluate the clinical implications of right ventricular function and its association with NT-proBNP, as well as its risk for adverse events in patients with HFpEF. The results demonstrated that worsening RV function and its ratio to pulmonary pressure were significantly associated with an increased risk of HF hospitalizations and cardiovascular death in these patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon, J. J. McMurray, B. Claggett, R. A. de Boer, D. DeMets, A. F. Hernandez, S. E. Inzucchi, M. N. Kosiborod, C. S. P. Lam, F. Martinez, S. J. Shah, A. S. Desai, P. S. Jhund, J. Belohlavek, C-E Chiang, C. J. W. Borleffs, J. Comin-Colet, D. Dobreanu, J. Drozdz, J. C. Fang, M. A. Alcocer-Gamba, W. Al Habeeb, Y. Han, J. W. Cabrera Honorio, S. P. Janssens, T. Katova, M. Kitakaze, B. Merkely, E. O'Meara, J. F. K. Saraiva, S. N. Tereshchenko, J. Thierer, M. Vaduganathan, O. Vardeny, S. Verma, V. N. Pham, U. Wilderang, N. Zaozerska, E. Bachus, D. Lindholm, M. Petersson, A. M. Langkilde

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Nicola Riccardo Pugliese, Pierpaolo Pellicori, Francesco Filidei, Nicolo De Biase, Pasquale Maffia, Tomasz J. Guzik, Stefano Masi, Stefano Taddei, John G. F. Cleland

Summary: Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome mainly affecting older people with many comorbidities. The management of HFpEF currently focuses on symptom control and treatment of comorbid conditions. Inflammation may play a key role in the development and progression of HFpEF.

CARDIOVASCULAR RESEARCH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction

James P. Curtain, Carly Adamson, Toru Kondo, Jawad Butt, Akshay S. Desai, Faiez Zannad, Jean L. Rouleau, Luis E. Rohde, Lars Kober, Inder S. Anand, Dirk J. van Veldhuisen, Michael R. Zile, Martin P. Lefkowitz, Scott D. Solomon, Milton Packer, Mark C. Petrie, Pardeep S. Jhund, John J. McMurray

Summary: This study examined the incidence of ventricular tachycardia (VT) and ventricular fibrillation (VF) in patients with heart failure and their relationship with mortality. The results showed that VT/VF events were uncommon but strongly associated with mortality in heart failure patients. These events seem to be markers of disease severity rather than risk of sudden death.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction

Elisa Dal Canto, Marielle Scheffer, Kirsten Kortekaas, Annet Driessen-Waaijer, Walter J. Paulus, Loek van Heerebeek

Summary: In patients with HFpEF, NP levels can be used to identify different stages of LV remodeling and myocardial tissue composition. This study found that HFpEF patients with high NP levels had worse LV stiffness and left atrial function, indicating advanced stage of HFpEF.

BIOMEDICINES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction

Virginia S. Hahn, Christopher Petucci, Min-Soo Kim, Kenneth C. Bedi, Hanghang Wang, Sumita Mishra, Navid Koleini, Edwin J. Yoo, Kenneth B. Margulies, Zoltan Arany, Daniel P. Kelly, David A. Kass, Kavita Sharma

Summary: In patients with heart failure with preserved ejection fraction (HFpEF), despite high prevalence of obesity and diabetes, myocardial fatty acid metabolism is lower and branched-chain amino acid (BCAA) metabolism is higher compared with heart failure with reduced ejection fraction (HFrEF), suggesting inadequate fuel utilization in HFpEF.

CIRCULATION (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Chronic intermittent mental stress promotes atherosclerotic plaque vulnerability, myocardial infarction and sudden death in mice

Lynn Roth, Miche Rombouts, Dorien M. Schrijvers, Katrien Lemmens, Gilles W. De Keulenaer, Wim Martinet, Guido R. Y. De Meyer

ATHEROSCLEROSIS (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension

Pedro Mendes-Ferreira, Carolina Maia-Rocha, Rui Adao, Maria Jose Mendes, Diana Santos-Ribeiro, Barbara Silvana Alves, Rui Joao Cerqueira, Paulo Castro-Chaves, Andre Pedro Lourenco, Gilles W. De Keulenaer, Adelino Ferreira Leite-Moreira, Carmen Bras-Silva

CARDIOVASCULAR RESEARCH (2016)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction

Shir Lynn Lim, Carolyn S. P. Lam, Vincent F. M. Segers, Dirk L. Brutsaert, Gilles W. De Keulenaer

EUROPEAN HEART JOURNAL (2015)

Add to Collection

Article Physiology

Effect of angiotensin II-induced arterial hypertension on the voltage-dependent contractions of mouse arteries

Paul Fransen, Cor E. Van Hove, Arthur J. A. Leloup, Dorien M. Schrijvers, Guido R. Y. De Meyer, Gilles W. De Keulenaer

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk

Leni Vandekerckhove, Zarha Vermeulen, Zhi Zhao Liu, Sonia Boimvaser, Andreas Patzak, Vincent F. M. Segers, Gilles W. De Keulenaer

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)

Add to Collection

Review Cardiac & Cardiovascular Systems

ErbB2 signaling at the crossing between heart failure and cancer

Zarha Vermeulen, Vincent F. M. Segers, Gilles W. De Keulenaer

BASIC RESEARCH IN CARDIOLOGY (2016)

Add to Collection

Article Neurosciences

A novel set-up for the ex vivo analysis of mechanical properties of mouse aortic segments stretched at physiological pressure and frequency

Arthur J. A. Leloup, Cor E. Van Hove, Ammar Kurdi, Sofie De Moudt, Wim Martinet, Guido R. Y. De Meyer, Dorien M. Schrijvers, Gilles W. De Keulenaer, Paul Fransen

JOURNAL OF PHYSIOLOGY-LONDON (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction

Constantijn Franssen, Sophia Chen, Andreas Unger, H. Ibrahim Korkmaz, Gilles W. De Keulenaer, Carsten Tschoepe, Adelino F. Leite-Moreira, Rene Musters, Hans W. M. Niessen, Wolfgang A. Linke, Walter J. Paulus, Nazha Hamdani

JACC-HEART FAILURE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Elastin fragmentation inatheroscleroticmice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death

Carole Van der Donckt, Jozef L. Van Herck, Dorien M. Schrijvers, Greetje Vanhoutte, Marleen Verhoye, Ines Blockx, Annemie Van Der Linden, Dries Bauters, Henri R. Lijnen, Judith C. Sluimer, Lynn Roth, Cor E. Van Hove, Paul Fransen, Michiel W. Knaapen, Anne-Sophie Hervent, Gilles W. De Keulenaer, Hidde Bult, Wim Martinet, Arnold G. Herman, Guido R. Y. De Meyer

EUROPEAN HEART JOURNAL (2015)

Add to Collection

Article Peripheral Vascular Disease

Applanation Tonometry in Mice A Novel Noninvasive Technique to Assess Pulse Wave Velocity and Arterial Stiffness

Arthur J. A. Leloup, Paul Fransen, Cor E. Van Hove, Marc Demolder, Gilles W. De Keulenaer, Dorien M. Schrijvers

HYPERTENSION (2014)

Add to Collection

Meeting Abstract Physiology

The Pressure-Dependency of Aortic Stiffness Is Modulated by Vascular Smooth Muscle Tone

Arthur Leloup, Cor Van Hove, Guido De Meyer, Gilles De Keulenaer, Paul Fransen

JOURNAL OF VASCULAR RESEARCH (2016)

Add to Collection

Meeting Abstract Physiology

Mechanical Activation of Mouse Aortic Segments at Physiological Preloads and Frequencies Promotes Basal Release of NO

Arthur Leloup, Cor Van Hove, Guido De Meyer, Gilles De Keulenaer, Paul Fransen

JOURNAL OF VASCULAR RESEARCH (2016)

Add to Collection

Meeting Abstract Cardiac & Cardiovascular Systems

Effect of neuregulin-1 on angiotensin II-induced ventricular inflammation, fibrosis and stiffening

Z. Zarha Vermeulen, L. Vandekerckhove, V. F. S. Segers, A. S. Hervent, G. W. De Keulenaer

EUROPEAN JOURNAL OF HEART FAILURE (2016)

Add to Collection

Meeting Abstract Cardiac & Cardiovascular Systems

Neuregulin-1 improves right ventricular function and attenuates monocrotaline-induced pulmonary arterial hypertension

P. Pedro Mendes-Ferreira, R. Adao, C. Maia-Rocha, B. S. Alves, D. Santos-Ribeiro, N. Hamdani, W. A. Linke, G. W. De Keulenaer, A. F. Leite-Moreira, C. Bras-Silva

EUROPEAN JOURNAL OF HEART FAILURE (2015)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.